Merck, Samsung Bioepis launch discounted Remicade alternative
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Seoul
MERCK & CO and South Korea's Samsung Bioepis Co Ltd said on Monday that they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine.
The US and South Korean drugmakers said that they would sell their version, to be called Renflexis, at 35 per cent discount to the list price of J&J's top-selling medicine, or about US$735 for a 100 mg dose.
Share with us your feedback on BT's products and services
TRENDING NOW
Autobahn Rent A Car directors declared bankrupt over S$50 million each owed to DBS
Amazon’s MGM Studios gains creative control over ‘James Bond’ franchise
UOB’s Wee Ee Cheong says S$4.9 billion Citi deal ‘paying off’ as Asean push accelerates
In taxing wealth, how far can Singapore push property owners?
